Top Biotech Penny Stocks to Watch Out for in 2026

Biotech penny stocks are low-priced shares in small pharma and drug development companies. It’s normal for a biotech penny stock to spike after good study results or drug pipeline news. But this volatility cuts both ways — these stocks often dilute their float to raise cash, hurting share value in the process.

May 2026 is a particularly interesting time for this sector. The broader market staged a strong April recovery after the Middle East ceasefire eased the geopolitical pressure that had been crushing growth stocks since January. Biotech has been one of the beneficiaries — but the names moving aren’t the pure speculative lottery tickets. The market is rewarding biotech companies with real revenue, real approvals, and real clinical momentum. Three of the five names on this list report earnings this week. That makes for a catalyst-dense environment where preparation is everything.

5 Biotech Penny Stocks to Watch in May 2026

My top 5 biotech penny stocks to watch for May 2026 are:

• NASDAQ: IBRX — ImmunityBio Inc. — The FDA Warning That Won’t Stop the Revenue Machine
• NASDAQ: IOVA — Iovance Biotherapeutics Inc. — The First FDA-Approved TIL Therapy Into Earnings
• NASDAQ: ADMA — ADMA Biologics Inc. — The Profitable Plasma Biotech Crushed Below Its Highs
• NASDAQ: OVID — Ovid Therapeutics Inc. — The 151% EPS Surprise With $856M in Milestone Payments
• NASDAQ: RXRX — Recursion Pharmaceuticals Inc. — The AI Drug Discovery Bounce Off the Lows

Don’t get too excited — biotech stocks are NOTORIOUS for diluting immediately after their runs…

There is no such thing as a sure thing. That goes double for the biotech sector.

These aren’t stock picks. They’re stocks I’m watching to see if they fit my patterns.

That’s what trading is. Don’t burn yourself out on low-potential plays. Be safe, and wait for the truly Grade-A setups…

There’s no guarantee that any of my watchlist picks will be tradeable. But if something happens, smart traders should be ready.

Here’s some background info on biotech penny stocks:

• What is the most promising biotech penny stock? A stock with a lot of volatility like ImmunityBio Inc. (NASDAQ: IBRX) is a good bet for the most promising biotech penny stock. Remember, we’re traders, not investors. We’re watching the stocks on this list for short-term moves, not predicting which of these stocks will still be around in 2030.
• What are the top 3 biotech penny stocks to buy now? My top 3 biotech penny stocks to buy now — as long as their price action is strong — are ImmunityBio Inc. (NASDAQ: IBRX), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), and ADMA Biologics Inc. (NASDAQ: ADMA).
• Which biotech penny stocks have a “Strong Buy” analyst rating? Analysts don’t give most biotech penny stocks strong buy ratings. These stocks are sketchy and unstable, and should never be investment targets. Always trade with a plan. Among these picks, IBRX has a Strong Buy consensus from 7 analysts, and ADMA just received a Buy initiation from Canaccord Genuity in late April.

Now, let’s get to the top biotech penny stocks to watch this month!

Top Biotech Penny Stock Picks

My top biotech penny stock picks for May — rated on chart pattern, price action history, and news — include the following:

Stock Ticker	Company	Performance (YTD)
NASDAQ: IBRX	ImmunityBio Inc.
NASDAQ: IOVA	Iovance Biotherapeutics Inc.
NASDAQ: ADMA	ADMA Biologics Inc.
NASDAQ: OVID	Ovid Therapeutics Inc.
NASDAQ: RXRX	Recursion Pharmaceuticals Inc.

The biotech penny stocks on this list are some of the wildest movers on the market…

Trading any of these stocks should be approached with a clear strategy and an understanding of the risks involved. I don’t trade until I see a setup I like.

Jump ahead to get to my trading plans for these top biotech penny stocks!

Best Biotech Penny Stocks for May 2026

These are the top 5 biotech penny stocks to watch in May 2026…

No, that doesn’t mean that I’ll trade them. Learn the patterns that work best for you — you might see a chance to use them with these stocks!

#1: ImmunityBio Inc. (NASDAQ: IBRX) — The FDA Warning That Won’t Stop the Revenue Machine

My first biotech penny stock pick is ImmunityBio Inc. (NASDAQ: IBRX).

IBRX is the most complicated name on this list — and the one with the most active news flow. The company’s ANKTIVA immunotherapy for bladder cancer is generating real, growing revenue: preliminary Q1 2026 net product revenue came in around $44 million, with a cash position of nearly $400 million backed by a $75 million non-dilutive financing secured this year. ANKTIVA is now commercially available in Saudi Arabia, and a new Phase 1 combination trial targeting pancreatic cancer just launched. Read more on what’s driving IBRX.

But here’s what you need to know heading into May 7 earnings: IBRX dropped over 20% in late March after the FDA issued a warning letter flagging misleading promotional claims about ANKTIVA’s route of administration. Multiple securities class action lawsuits followed. H.C. Wainwright is sticking with its Buy rating. Seven analysts have a Strong Buy consensus with average targets implying nearly 80% upside from current prices. This is a stock where the headline risk is real and the catalyst risk is binary. Know that before touching it.

Why I Like It

IBRX has something most biotech penny stocks don’t: actual revenue. Around $44 million in a single quarter is not a clinical-stage story — it’s a commercial one. The FDA warning is a known, disclosed headwind. May 7 earnings will either show the revenue ramp continuing despite the controversy or give sellers more ammunition. Either way, it moves. I wait for the setup, not the news.

Trade Potential:

• Bullish Scenario: A clean Q1 earnings beat with ANKTIVA revenue above $45 million and management commentary addressing the FDA warning constructively could push IBRX back toward $9 to $10. Analyst consensus is nearly double the current price.
• Bearish Scenario: Any escalation of the FDA warning into a formal action or a revenue miss on Q1 could push IBRX back below $6. With class action lawyers circling, bad news gets amplified fast.

IBRX checks the boxes for a volatile biotech setup: real revenue, a controversial catalyst, a hard earnings date, and institutional eyes on it. Keep it on radar — with a stop.

#2: Iovance Biotherapeutics Inc. (NASDAQ: IOVA) — The First FDA-Approved TIL Therapy Into Earnings

My second biotech penny stock pick is Iovance Biotherapeutics Inc. (NASDAQ: IOVA).

IOVA has a distinction that matters in biotech: its lead product Amtagvi is the first and only FDA-approved T cell therapy for a solid tumor indication. That’s not a pipeline story — it’s a commercial reality. The company reported full-year 2025 revenue of $264 million and Q4 revenue of $87 million, beating estimates. The TIL therapy platform is expanding: early trial data showed a 50% response rate in aggressive soft-tissue sarcomas, and a registrational trial is planned for 2026. Read more on Iovance’s clinical expansion.

The stock is trading in the low-to-mid $3s, with a 52-week range from the mid-$1s to the high $5s. Q1 2026 earnings are May 7 before the market open, with analysts forecasting revenue in the high $70 million range. The main overhang: a proposed increase in authorized shares that raises dilution concerns. Float expansion is the biotech tax — always factor it in.

Why I Like It

Amtagvi is a real product with real patients and real revenue — not a hoped-for future approval. The sarcoma data adds another potential indication on top of the existing melanoma label. May 7 is the hard catalyst. If revenue beats and the dilution concern gets addressed on the call, the setup back toward the mid-$4s to $5 zone is clean.

Trade Potential:

• Bullish Scenario: A May 7 beat above $80 million in Q1 revenue with constructive comments on the share authorization and sarcoma trial timing could push IOVA back toward the mid-to-high $4s. The 52-week high is the longer-run reference point.
• Bearish Scenario: A revenue miss or a large dilutive offering could push IOVA back toward the mid-to-high $2s. At current prices, the stock is already well off its highs — bad news accelerates the move fast.

Amtagvi is a proven platform with growing commercial traction. May 7 is the date that resolves the near-term setup.

#3: ADMA Biologics Inc. (NASDAQ: ADMA) — The Profitable Plasma Biotech Crushed Below Its Highs

My third biotech penny stock pick is ADMA Biologics Inc. (NASDAQ: ADMA).

ADMA is the unusual name in this group — it’s actually profitable, which almost disqualifies it from the biotech penny stock category. But the stock is trading well below its 52-week high, which makes it as interesting as any pre-revenue pipeline play right now. The company just reported record full-year 2025 results: total revenue of $510 million up roughly 20% year-over-year, ASCENIV revenue up over 50%, adjusted net income of $161 million, and adjusted EBITDA of $231 million. Read more on ADMA’s commercial momentum.

Canaccord Genuity initiated coverage with a Buy rating in late April. Two analysts have a Buy consensus with average targets implying nearly triple upside from current prices. ADMA makes plasma-derived biologics — BIVIGAM, ASCENIV, and Nabi-HB — with real patients, real hospitals, and real recurring revenue. Q1 2026 earnings are May 6 after market close.

Why I Like It

A profitable biotech trading at a fraction of its 52-week high with a fresh analyst initiation and a May 6 earnings catalyst is the kind of setup that doesn’t come around often in this sector. ADMA doesn’t need a drug approval — it’s already approved, already commercial, and already growing. If Q1 shows the revenue trajectory continuing, the market may start pricing this as the specialty pharma story it is.

Trade Potential:

• Bullish Scenario: A Q1 beat with ASCENIV revenue tracking toward $100 million and EBITDA margin expansion could push ADMA back toward the mid-teens. Analyst targets imply substantially more upside beyond that.
• Bearish Scenario: Any guidance cut or margin compression in Q1 would validate the selloff from the highs. Below the low teens and the stock risks testing the next area of prior support.

ADMA is one of the few names in the biotech penny stock universe where the fundamental case alone can defend a trade. That’s rare — and it makes the setup worth watching.

#4: Ovid Therapeutics Inc. (NASDAQ: OVID) — The 151% EPS Surprise With $856M in Milestone Payments

My fourth biotech penny stock pick is Ovid Therapeutics Inc. (NASDAQ: OVID).

OVID doesn’t get the attention it deserves. The company just reported a 151% EPS surprise in Q4 2025: earnings came in at $0.06 per share versus a -$0.12 consensus estimate, and revenue came in nearly 10x above estimates. More importantly, the company disclosed eligibility to receive up to $856 million in milestone payments, including a significant upfront payment. Read what’s driving OVID.

The stock is trading around $2, with analyst targets near double the current price. Ovid focuses on rare neurological conditions, and rare disease biotechs have a structural advantage: FDA orphan drug designations reduce the approval barrier, and patient populations, while small, command premium pricing. Q1 2026 earnings are May 13. The float is small. This is a classic low-float biotech with a massive milestone payment disclosure sitting in the background.

Why I Like It

A 151% EPS beat plus a near-10x revenue beat plus $856 million in milestone payments is the kind of catalyst stack that gets biotech traders paying attention. The price hasn’t run yet — which means either the market hasn’t figured it out, or there’s something to be cautious about. Either way, I watch the tape. A move above the low-to-mid $2s on volume would be the first signal that momentum is building ahead of May 13 earnings.

Trade Potential:

• Bullish Scenario: A clean breakout on volume ahead of May 13 earnings, with any confirmation on the milestone payment timing, could push OVID toward analyst targets around $4. Low float accelerates moves in both directions.
• Bearish Scenario: Failure to hold the $2 level and the stock gives back any pre-earnings bid. Below the high $1s and the setup is broken — wait for a new base before re-engaging.

OVID is the kind of small-float biotech that goes from ignored to violent in a single session when the right catalyst arrives. The milestone payment disclosure is the hook. May 13 earnings is the hard date.

#5: Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) — The AI Drug Discovery Bounce Off the Lows

My fifth biotech penny stock pick is Recursion Pharmaceuticals Inc. (NASDAQ: RXRX).

RXRX sits at the intersection of two of the most powerful themes in the market right now: AI and drug discovery. The company has built a TechBio platform that uses machine learning, automation, and massive biological datasets to identify drug candidates at scale — a fundamentally different approach from traditional trial-and-error pharma R&D. The stock hit an all-time low in late March, then bounced after a board leadership transition announcement that the market read as stabilizing. Read more on Recursion’s AI drug platform.

The Q4 2025 results were a genuine beat: revenue of $35 million versus a $24 million estimate, a 44% upside surprise. Cash stands at roughly $750 million — enough runway to execute. A new Chief Medical Officer was hired in March. The Buy consensus analyst target sits well above current prices. Q1 2026 earnings are May 6 before the market open.

Why I Like It

Bounces off all-time lows with real cash and a real revenue beat behind them are the cleanest setups in the biotech world. RXRX has over $700 million in cash — it’s not going anywhere. The AI drug discovery angle gives it a story that retail traders understand and institutional managers are actively studying. May 6 earnings is the next defined catalyst. If Q1 shows revenue holding above Q4 levels, the bounce continues.

Trade Potential:

• Bullish Scenario: A Q1 revenue beat combined with positive pipeline catalyst commentary could push RXRX toward the mid-to-high single digits. Analyst targets in the $10 area are the reference point for how far this can move on a sentiment shift.
• Bearish Scenario: A Q1 revenue miss or any clinical setback could push RXRX back toward its all-time low area. The stock is still in a downtrend on the long-term chart — don’t confuse a bounce with a reversal until price confirms.

RXRX is the AI biotech play for traders who want a story that works across two hot sectors. May 6 is the catalyst — wait for the chart to tell you the setup is ready before entering.

*Past performance does not indicate future results

Biotech Stocks Under $5

The allure of hot sector stocks priced under $5 is undeniable in biotech. These stocks represent a unique blend of opportunity and volatility. The biotech industry is evolving fast, with advancements across drug development, gene editing, and AI-assisted drug discovery making the sector a magnet for traders looking for the next big move. The gains here can be proportionately greater than those from more established stocks — even minor positive developments or clinical trial results can send prices soaring.

However, it’s crucial to approach these opportunities with a clear strategy and an understanding of the risks. The volatility of penny stocks combined with the speculative nature of biotech ventures means that while the potential for rapid gains is significant, the risk of losses is equally high. Conduct thorough research, look beyond the hype, and never hold these stocks as long-term investments — only trade them with a plan.

The key to trading biotech stocks under $5 is selectivity and discipline. It’s about leveraging the explosive potential of the sector while managing risk meticulously. Focus on companies with meaningful catalysts — real clinical data, upcoming FDA decisions, government contracts — and keep your position sizing tight. Cut losses quickly when the setup fails.

Upcoming Biotech Companies

Keep an eye on the news for new biotech names entering the market through IPOs or SPAC mergers. These are often where the most explosive short-term setups live — a fresh listing with a small float and a hot story can move 100% in a day. But be cautious: not every new biotech company will deliver. The failure rate is high. Always do your due diligence before adding any stock to your watchlist.

It’s also a good idea to keep tabs on the overall market sentiment toward biotech. When the FDA is approving drugs at a healthy rate and clinical trial success stories are making headlines, the entire sector can lift. When sentiment turns negative, even good news can struggle to hold gains. Monitoring sector momentum is just as important as monitoring individual catalysts.

What Are Biotech Penny Stocks?

Biotech penny stocks are shares of small biotechnology companies that trade at relatively low prices — typically under $5 per share. These companies are often in the early stages of development, focusing on innovative medical treatments and technologies. The low price point makes these stocks accessible to many traders, but it also means they come with significant risks.

These companies are heavily involved in the discovery and development of new medicines and therapies. Some are working on groundbreaking treatments for conditions like Alzheimer’s disease, cancer, or rare neurological disorders. Due to the speculative nature of these ventures, biotech penny stocks can exhibit extreme volatility — offering both substantial upside potential and considerable downside risk. A single clinical trial result can double or cut a stock in half in a single session.

The allure of biotech penny stocks lies in their growth potential. A successful drug candidate reaching commercialization can generate massive gains. But the path to success is fraught with challenges: rigorous testing, regulatory approvals, and the constant risk of dilution. Understanding the inherent risks and rewards is crucial for anyone considering trading in this sector.

How Do Biotech Penny Stocks Work?

Biotech penny stocks operate in the high-stakes arena of medical research and development. These stocks represent companies that are often in the process of testing new drugs or medical devices. The success or failure of these tests can dramatically affect the stock price. Positive results in clinical trials can lead to significant price spikes, while negative outcomes can cause sharp declines — sometimes 50% or more in a single day.

Understanding the catalyst calendar is essential. FDA decision dates, clinical trial data readouts, earnings reports with pipeline updates, and government contract awards are all events that can move these stocks. The best trades come when you know a catalyst is coming, the setup is clean, and you have a defined entry and exit before the news drops.

Risks of Investing in Biotech Penny Stocks

First of all — never invest in any penny stock. You only want to be trading these stocks… here’s why…

Higher Failure Rates

Biotech companies have some of the highest failure rates in any industry, especially in clinical trials. If a drug doesn’t receive approval or shows poor results in a trial, the share price can collapse overnight. Most drugs that enter clinical trials never reach the market.

Regulatory Uncertainties

The biotech sector is heavily regulated by the FDA and international equivalents. Companies must navigate multiple phases of clinical trials before bringing a product to market. A Complete Response Letter from the FDA, a clinical hold, or a warning letter — like the one IBRX received in March 2026 — can be devastating for the stock price regardless of the underlying business quality.

Dilution Risk

Many biotech penny stocks have limited financial resources and are dependent on investor funding. When the money runs low, they issue new shares — diluting existing shareholders and pushing the price down. This is one of the most common ways traders get hurt in this niche. Always check the cash runway before entering a position.

Top Tips for Trading Biotech Penny Stocks

When it comes to biotech penny stocks, you’ve got to be on your A-game. Here are my top tips beyond the numbers and data:

• Understand the management team behind the company and their track record. People make a company go. A management team that has successfully brought drugs to market before is a meaningful signal.
• Use a reliable trading platform that gives you quick access to the market, real-time scanning, and Level 2 data. Slow platforms kill you in fast-moving biotech names.
• Pay attention to patient response data during clinical trials — but remember you’re not a medical expert. Focus on whether the market is reacting positively to the data, not on your own interpretation of efficacy.
• Look at the full revenue picture, not just top-line headline numbers. For commercial-stage biotechs like ADMA and IOVA, margin trends and revenue consistency matter.
• Do your due diligence and make informed decisions. Never enter a biotech trade without knowing the next catalyst date, the float size, and your stop level.

Research the Company

Before trading any biotech penny stock, research the company behind it. Look at their pipeline — how many drugs are in clinical trials, what stage, and what the timeline is for data readouts. Check their financials for cash runway. Read about their management team. The more information you have, the better your odds of being in the right place at the right time.

Understand Your Trading Approach

Are you looking for quick gains on a catalyst spike, or are you building into a setup ahead of a known event date? Understanding your approach will help you pick the right stocks and size positions appropriately. A pre-earnings setup requires different position sizing than a post-spike bounce trade.

Know the Biotech Industry Landscape

Understanding the biotech industry as a whole gives you better perspective on individual stocks. Keep an eye on FDA approval trends, breakthrough therapy designations, and upcoming data readouts across the sector. When biotech sentiment is hot — like it has been in April and May 2026 as the broader market recovered — the entire sector can lift, making setups across the board cleaner.

Avoid OTC and Pink Sheet Biotech Stocks

Over-the-counter and pink sheet stocks are not subject to the same regulatory oversight as stocks listed on major exchanges like the NYSE and Nasdaq. They’re riskier, harder to research, and more susceptible to manipulation. Stick to exchange-listed biotechs where you have access to reliable financial disclosures and real trading volume data.

Be Wary of Promotional Pumps

Be cautious of biotech stocks being heavily promoted in online forums, social media, or email newsletters. These are often pump-and-dump schemes designed to inflate the stock price so the promoters can sell. If you didn’t find the stock through your own research or a catalyst you understand, the risk of being on the wrong side of a pump is high.

Only Trade Biotech Penny Stocks With Volume

Look for stocks with high trading volume. Low-volume biotech stocks are more susceptible to price manipulation and harder to exit quickly when the move turns against you. Volume is the fuel for the move and the exit liquidity you need when things go wrong.

Understand the Hit and Run Approach

In the world of biotech penny stocks, it’s often better to be a trader than an investor. Take your profits when the trade reaches your target, and move on to the next opportunity. Holding through the catalyst that caused the spike is where most traders give back their gains.

How To Make Money in Biotech Stocks

The key to making money in biotech stocks is research, timing, and a solid trading plan. These stocks are risky, but they offer some of the best opportunities for high-percentage moves in the market. The key word is opportunities — not guarantees. Always trade with money you can afford to lose, and never size into a biotech position larger than your risk tolerance can handle.

Get a 14-day trial of StocksToTrade for just $7 for access to one of the most powerful stock trading and scanning platforms available — including real-time biotech news alerts and catalyst tracking.

Have you traded biotech penny stocks? Write “I always trade with a plan” in the comments!

FAQs

How Do I Trade Biotech Stocks?

Trading biotech stocks starts with knowing the catalyst calendar. FDA decision dates, clinical trial readouts, and earnings reports are the events that move these stocks. Identify the catalyst, understand the setup, size your position appropriately for the binary risk, and have your stop defined before you enter. Never average down into a failing biotech position.

Why Do Traders Buy Penny Stocks?

Traders buy penny stocks for the potential of high percentage returns in a short period. These low-priced stocks offer the opportunity for significant gains when the right catalyst arrives — but they come with proportionally higher risks. The key is treating them as trading vehicles, not investments.

How To Manage Risk in Biotech Penny Stocks?

Risk management in biotech penny stocks comes down to three things: position sizing, stop losses, and catalyst awareness. Keep positions small relative to your account. Set your stop before you enter, and honor it when it’s hit. Know every upcoming catalyst for the stocks you hold, and don’t get caught holding through a binary event without a plan for both outcomes.

What Is the Pattern Day Trading Rule and How Does It Affect Biotech Trading?

The Pattern Day Trading (PDT) rule was recently eliminated. On April 14, 2026, the SEC approved FINRA’s proposal to scrap it entirely — the $25,000 minimum equity requirement, the day trade counting, the 90-day account freezes — all gone. The official effective date is June 4, 2026, with brokers having up to 18 months to fully implement the new framework.